

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/761,787
Filing Date	January 21, 2004
First Named Inventor	Weiner, et al.
Art Unit	1617
Examiner	Jennifer M. KIM
Attorney Docket No.	ACADIA.031A

(Multiple sheets used when necessary)

SHEET 1 OF 3

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/JK/	1	3,501,483	03-17-1970	Howell et al.	
	2	3,532,702	10-06-1970	Howell et al.	
	3	3,663,696	05-16-1972	Howell et al.	
	4	4,308,207	12-29-1981	Hunziker et al.	
	5	4,406,900	09-27-1983	Hunziker et al.	
	6	4,663,453	05-05-1987	Glamkowski	
	7	5,344,828	09-06-1994	Sawanishi, et al.	
	8	5,602,120	02-11-1997	Fu et al.	
	9	5,602,121	02-11-1997	Fu	
	10	5,814,628	09-29-1998	Fu et al.	
	11	5,834,459	11-10-1998	Fu	
	12	2006/0199807 A1	09-07-2006	Weiner et al.	
	13	2007/0197502	08-23-2007	Ek et al.	
/JK/	14	2007/0275957 A1	11-29-2007	Weiner et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/JK/	15	CH 436 297	05-31-1967	Dr. A. Wander AG		√
	16	CS 0179793 B	11-30-1977	Protiva et al.		
	17	GB 1 164 360	09-17-1969	American Cyanamid Company		
	18	GB 1 218 045	01-06-1971	American Cyanamid Company		
	19	GB 1 355 866	06-05-1974	Wander Ltd.		
	20	GB 1 418 363	12-17-1975	Wander Ltd.		
	21	WO 1996/18621	06-20-1996	Allelix Biopharma		
	22	WO 1996/18623	06-20-1996	Allelix Biopharma		
	23	WO 1996/18629	06-20-1996	Allelix Biopharma		
/JK/	24	WO 2006/017614	02-16-2006	Acadia Pharmaceuticals, Inc.		

Examiner Signature /Jennifer Kim/

Date Considered 04/15/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 2 OF 3

Application No.	10/761,787
Filing Date	January 21, 2004
First Named Inventor	Weinert, et al.
Art Unit	1617
Examiner	Jennifer M. KIM
Attorney Docket No.	ACADIA.031A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/JK/	25	BUERKI et al. "Dibenzo-epines: effect of the basic side-chain on neuroleptic activity", <i>Eur J Med Chem. - Chimica Therapeutica</i> (1978) 13(5): 479-485.	
	26	CACCHI et al. "A convenient synthesis of nitrogen-containing heterocycles bearing amino substituents from heteroaryl triflates", <i>Synlett</i> (1997) 12:1400-2.	
	27	Encyclopedia of Drugs, Moscow, (2001) RLS 421-422	
	28	KONSTANTINOVA et al. "11-substituted oiktyridubenz [b,f][1,4] oxazepines", <i>Khimiya Geterotsiklicheskikh Soedinenii</i> , (1989) 4:451-454.	√
	29	MELTZER et al "Plasma clozapine levels and the treatment of L-DOPA-Induced Psychosis in Parkinson's Disease" <i>Neuropsychopharma.</i> (1995) 12(1):39-45-7.	
	30	MIKHAILOV Handbook on Clinical Pharmacology S-Pb (2001) <i>Foliant</i> 425-429.	
	31	MOODY et al. "Fungal transformation of the tricyclic antidepressant amoxapine: Identification of N-carbomethoxy compounds formed as artifacts by phosgene in chloroform used for the extraction of metabolites", <i>Biotransformation and Biocatalysis</i> (2001), 19: 155-161.	
	32	NAGARAJAN et al. "Piperazinylbenzonaphthoxazepines with CNS depressant properties", <i>European J. of Medicinal Chemistry</i> (1986), 21(1): 21-6.	
	33	PARNAS et al. "Expression and localization of muscarinic receptors in P19-derived neurons", <i>J of Mol Neuroscience</i> (1998) 10:17-29.	
	34	Practical Handbook on Treatment of Schizophrenia, "Use of neuroleptics upon schizophrenia", Chapter, <i>SMM Psychiatry</i> (2004) 83-112.	
	35	SCHMUTZ et al. "Über in 11-Stellung amino-substituierte Dibenzo[b,f]-1,4-thiazepine und -oxazepine - 9. Mitteilung über siebengliedrige Heterocyclen", <i>Helvetica Chimica Acta</i> (1967), 50(1): 245-54.	
	36	SCHMUTZ et al. "Constitution chimique et action pharmacologique d'un nouveau groupe de neuroleptiques tricycliques", <i>Chimica Therapeutica</i> (1967), 2(6): 424-9.	
	37	SILVEIRA et al. "Shared psychotic disorder: A critical review of the literature", <i>Can J Psychiatry</i> (1995) 40:389-95.	
	38	SINDELAR et al. "Neurotropic and psychotropic agents", <i>Collection of Czechoslovak Chemical Communications</i> (1978), 43(1): 309-15.	
	39	SUMNER et al. "Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs" <i>Psychopharmacology</i> (2004) 171:306-321.	
	40	WEBER et al. "Analysis of the pharmacological properties of clozapine analogs using molecular electrostatic potential surfaces", <i>J. of Molecular Graphics</i> (1986) 4(1): 58-60, 38.	
	41	Office Action dated December 31, 2007 in USSN 11/733,476, filed April 10, 2007.	
↓	42	Office Action dated December 31, 2007 in USSN 11/417,441, filed May 3, 2006	
/JK/	43	Office Action dated January 10, 2008 in USSN 11/096,756, filed March 31, 2005	

Examiner Signature /Jennifer Kim/

Date Considered 04/15/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/761,787	
	Filing Date	January 21, 2004	
	First Named Inventor	Weimer, et al.	
	Art Unit	1617	
(Multiple sheets used when necessary)		Examiner	Jennifer M. KIM
SHEET 3 OF 3		Attorney Docket No.	ACADIA.031A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/JK/	44	Office Action dated January 16, 2008 in USSN 11/417,069, filed May 3, 2006.	
	45	Office Action dated February 11, 2008 in USSN 10/913,117, filed August 5, 2004.	
	46	International Preliminary Report on Patentability dated January 16, 2006 in PCT/US04/043224, filed 12/21/2004.	
	47	International Preliminary Report on Patentability dated May 2, 2005 in PCT/US04/001509, filed 01/21/2004	
	48	International Preliminary Report on Patentability dated July 3, 2006 in PCT/US05/010876, filed 03/31/2005.	
	49	International Preliminary Report on Patentability dated July 27, 2007 in PCT/US2006/012463, filed 04/03/2006.	
	50	International Preliminary Report on Patentability dated February 6, 2007 in PCT/US05/027645, filed 08/04/2005.	
↓ /JK/	51	Written Opinion dated January 9, 2008 in PCT/US2006/042464 filed 10/31/2006 (Rule 66).	
	52	Russian Examination Report dated October 18, 2007 in Russian Application No. 2005128614/04(029879), filed 08/22/2005.	√

4928968:abt
022905

Examiner Signature	/Jennifer Kim/	Date Considered	04/15/2008
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T¹ - Place a check mark in this area when an English language Translation is attached.